Meningioma natural history
|
Meningioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningioma natural history On the Web |
|
American Roentgen Ray Society Images of Meningioma natural history |
|
Risk calculators and risk factors for Meningioma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Natural History
Complications
Prognosis
- The table below lists common prognostic factors for meningioma:
| Prognostic Factor | Description |
| Stage | Advanced stages of multiple myeloma are associated with poor prognosis.[1] |
| Kidney function | An elevated level of creatinine is associated with poor prognosis.[1] |
| Labelling index | The labeling index indicates how fast the cancer cells are growing. A high plasma cell labeling index (PCLI) or proliferation (reproduction) rate is associated with poor prognosis.[1] |
| Age | Older patients have worse prognosis than younger patients.[1] |
| Chromosome changes | Cytogenetic analysis of multiple myeloma cells may be of prognostic value, with deletion of chromosome 13, non-hyperdiploidy and the balanced translocations t(4;14) and t(14;16) conferring a poorer prognosis. The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.[1][2] |
| Assocciated plasma cell disorder | The presence of plasma cell leukemia or soft tissue plasmacytoma is associated with a particularly poor prognosis among patients with multiple myeloma.[3] |
| Performance status | Performance status is ranked on a 0–4 scale. The lower the number, the healthier and more active the person is, and the better the prognosis. Performance status is important in multiple myeloma because people who are healthier can withstand more intensive treatment.[1] |
| Beta-2-microglobulin | A higher level of beta-2-microglobulin is associated with poor prognosis.[1] |
| Albumin level | A lower albumin level is associated with poor prognosis.[1] |
| Lactate dehydrogenase level | A higher level of lactate dehydrogenase (LDH) is associated with poor prognosis.[1] |
| Response to treatment | People whose cancer responds to treatment and goes into complete remission have a better prognosis than people whose cancer does not respond to the initial treatment.[1] |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Multiple myeloma. Canadian cancer society (2015)http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/prognosis-and-survival/?region=mb Accessed on September, 20th 2015
- ↑ Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Prognosis Accessed on September, 20th 2015
- ↑ Plasma cell neoplasm. Cancer.gov (2015)http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#link/_40_toc